Citations

Clear

16280 citation(s) found for "Yu, David".

Magnetic resonance assessment of parenchymal elasticity in normal and edematous, ventilator-injured lung
McGee, Kiaran P. , Mariappan, Yogesh K. , Hubmayr, Rolf D., Carter, Rickey E. , Bao, Zhonghao , Levin, David L. , Manduca, Armando , Ehman, Richard L. , Carter, Rickey E , Mariappan, Yogesh Kannan

Mayo Clinic

Journal of Applied Physiology | June 8, 2012 | Volume: 113 | Issue: 4 | Pages: 666-676

10.1152/japplphysiol.01628.2011 | PMID 22678969 Get It

Magnetic resonance elastography (MRE) is a MR imaging method capable of spatially resolving the intrinsic mechanical properties of normal lung parenchyma. We tested the hypothesis that the mechanical properties of edematous lung exhibit local properties similar to those of a fluid-filled lung at transpulmonary pressures (Ptp) up to 25 cm H2O. Pulmonary edema was induced in anesthetized female adult Sprague-Dawley rats by mechanical ventilation to a pressure of 40 cm H2O for ∼30 min. Prior to imaging the wet weight of each ex vivo lung set was measured. MRE, high-resolution T1-weighted spin echo and T2* gradient echo data were acquired at each Ptpfor both normal and injured ex vivo lungs. At Ptps of 6 cm H2O and greater, the shear stiffness of normal lungs was greater than injured lungs ( P ≤ 0.0003). For Ptps up to 12 cm H2O, shear stiffness was equal to 1.00, 1.07, 1.16, and 1.26 kPa for the injured and 1.31, 1.89, 2.41, and 2.93 kPa for normal lungs at 3, 6, 9, and 12 cm H2O, respectively. For injured lungs MRE magnitude signal and shear stiffness within regions of differing degrees of alveolar flooding were calculated as a function of Ptp. Differences in shear stiffness were statistically significant between groups ( P < 0.001) with regions of lower magnitude signal being stiffer than those of higher signal. These data demonstrate that when the alveolar space filling material is fluid, MRE-derived parenchymal shear stiffness of the lung decreases, and the lung becomes inherently softer compared with normal lung.
Potentially curative treatment in patients with hepatocellular cancer—results from the liver cancer research network
Kanwal, Fasiha , Befeler, Alex S. , Chari, Ravi S., Marrero, Jorge A. , Kahn, Jeffrey , Afdhal, Nezam H. , Morgan, Timothy R. , Roberts, Lewis R. , Mohanty, Smruti R. , Schwartz, Jonathan M., VanThiel, David, Li, J., Zeringue, Angelique , DIBISCEGLIE, A, Roberts, Lewis R

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 7, 2012 | Volume: 36 | Issue: 3 | Pages: 257-265

10.1111/j.1365-2036.2012.05174.x | PMID 22670798 Get It

SummaryBackgroundThe extent to which potentially curative therapies are used in patients with hepatocellular cancer (HCC) and their related outcomes are unknown in the US.AimTo determine the rate and outcomes of potentially curative treatment in patients with HCC.MethodsEleven US centers followed patients with HCC between 2001 and 2007. We determined rates of liver transplantation, surgical resection, or tumour ablation during follow‐up, examined differences in adjusted survival of patients receiving these treatments, and determined the factors associated with receipt of potentially curative treatment.ResultsOf the 267 patients, 76 (28%) patients had early HCC, defined as Child A or B cirrhosis, with a solitary HCC or ≤3 nodules, each ≤3 cm. Of these, 53 (69.7%) received curative treatment. Thirty six percent of patients with non‐early HCC received curative treatment. Compared to patients with non‐early HCC who did not receive curative treatment, patients with early HCC and curative treatment had the best survival [hazard ratio, HR = 0.19 (95% CI, 0.08–0.42)] followed by patients with advanced HCC who received curative treatment [HR = 0.37 (95% CI, 0.22–0.64)]. Baseline performance status was significantly associated with receipt of curative treatment as well as survival after adjusting for demographics, clinical characteristics, and HCC stage.ConclusionsIn this multicenter database, most of the patients with early HCC received potentially curative treatment. However, only 28% of patients had early HCC. One‐third of patients with non‐early HCC also underwent curative therapy. Potentially curative treatment improved survival and this effect was seen in patients with early as well as non‐early HCC.
Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation
Bleeker, Jonathan , Pellikka, Patricia A. , Dingli, David , Dispenzieri, Angela , Hayman, Suzanne R. , Kumar, Shaji , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Larson, Dirk R. , Buadi, Francis K. , Hogan, William J. , Rajkumar, S Vincent , Dispenzieri, Angela , Pellikka, Patricia A , Dingli, David

Mayo Clinic

European Journal of Haematology | June 1, 2012 | Volume: 89 | Issue: 3 | Pages: 228-235

10.1111/j.1600-0609.2012.01815.x | PMID 22672722 Get It

AbstractBackgroundCardiac complications following hematopoietic stem cell transplantation (HSCT) are emerging as a significant concern given the increasing utilization of HSCT for a variety of hematologic malignancies.MethodsWe utilized an existing database to determine the frequency of cardiac dysfunction (CD), namely a decrease in left ventricular ejection fraction, following conditioning with high‐dose melphalan (HDM) and autologous HSCT for multiple myeloma (MM) and systemic amyloidosis (AL). We then performed a case–control study to examine variables associated with increased risk of CD in this population.ResultsIn MM patients undergoing HSCT, the rate of CD was 1.6% (17/1050, 95% CI: [0.9, 2.6]). None of the examined pre‐HSCT variables or HDM dose were significantly associated with development of CD in this population. In patients with AL, the rate of CD was 5.6% (24/426, 95% CI: [3.6, 8.3]). On univariate analysis, decision to administer an HDM dose <200 mg/m2 [odds ratio (OR): 4.59 (1.27–16.57) P = 0.02], pretransplant left ventricular ejection fraction <60% [OR: 17.78 (2.29–138.33) P = 0.006], and documented amyloid involvement of ≥3 organs [OR: 4.0 (1.03–15.6) P = 0.046] were associated with the development of CD in the AL population. No other examined peri‐transplant factors were associated with development of CD.ConclusionTo our knowledge, this is the first series to report a significant rate of CD following HDM conditioning and autologous HSCT in patients with AL.
Prevalence of extravertebral cement leakage after vertebroplasty: procedural documentation versus CT detection
Martin, Douglas , Rad, Arash Ehteshami, Kallmes, David F.

Mayo Clinic

Acta Radiologica | May 27, 2012 | Volume: 53 | Issue: 5 | Pages: 569-572

10.1258/ar.2012.120222 | PMID 22637642 Get It

Background Reported incidence of extravertebral cement leakage after vertebroplasty varies widely across studies. Purpose To retrospectively compare the relative detection rates of extravertebral leakage noted under intra-procedural fluoroscopic surveillance, postprocedure plain radiographs, and postprocedure computed tomography (CT) in a cohort of patients undergoing vertebroplasty. Material and Methods With IRB approval, we retrospectively identified 181 patients with 277 levels treated with percutaneous vertebroplasty among a total of 1255 patients undergoing vertebroplasty between 1999 and 2010 who had subsequently undergone a CT examination that included the treated level(s). Categories of leakage were paravertebral, end plate, epidural, and prevertebral venous leakage. CT-detected leak rates were then compared to those noted on the vertebroplasty procedure reports and the archived fluoroscopic images for this same cohort using Pearson's χ 2 test. Results One hundred and forty-nine (82%, 95% CI 76–87%) of 181 patients demonstrated evidence of some type of leakage on CT at one or more treated levels. Sixty-two (34%, 95% CI 28–42%) and seventy-seven (50%, 95% CI 43–57%) of 149 CT-detected leaks were reported in the procedural dictation or detected on plain radiography ( P = 0.01 and 0.006, respectively). The most common type of leakage noted on CT was end plate ( n = 81, 45%, 95% CI 38–52%), followed by paravertebral ( n = 64, 35%, 95% CI 29–43%), epidural ( n = 36, 20%, 95% CI 15–26%), and prevertebral venous ( n = 32, 18%, 95% CI 13–24%). Conclusion Cement leakage after vertebroplasty is common and is often not reported by operators in procedural dictations. CT detects substantially more leaks than plain radiography.
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set
Thomas, David M. , Yothers, Greg , Green, Erin , Blanke, Charles D. , Labianca, Roberto , Shi, Qian , Gramont, Aimery de , Sargent, Daniel J. , Hubbard, Joleen M. , O’Connell, Michael J. , Bleyer, Archie , Sargent, Daniel J , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | May 21, 2012 | Volume: 30 | Issue: 19 | Pages: 2334-2339

10.1200/jco.2011.41.1975 | PMID 22614981 Get It

Purpose Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
D’Souza, Anita , Lacy, Martha Q. , Kumar, Shaji , Hayman, Suzanne R. , Dingli, David , Zeldenrust, Steven R., Kyle, Robert A. , Ansell, Stephen M. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Porrata, Luis F. , Litzow, Mark R. , Gastineau, Dennis A., Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Hogan, William J. , D'Souza, Anita , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | May 20, 2012 | Volume: 120 | Issue: 1 | Pages: 56-62

10.1182/blood-2012-04-423178 | PMID 22611150 Get It

AbstractThe POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT). While clinical improvement is nearly universal in these patients, the long-term outcomes after transplantation are unclear. We therefore assessed the long-term clinical outcomes of 59 POEMS patients treated with ASCT at our institution. With a median follow-up of 45 months, 14 patients have progressed with a progression-free survival of 98% and 75% at 1 and 5 years, respectively. Factors associated with progression have included an IgG-λ monoclonal component (hazard ratio [HR] 7.5; 95% confidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emission tomography (HR 6.4; 95% CI, 1.2-120; P = .03), lack of complete hematologic response (HR 5.4; 95% CI, 1.8-16.7; P = .003), and patients aged 50 years or younger at transplantation (HR 4.4; 95% CI, 1.3-20; P = .01). The most common progression events have been radiologic followed by rising VEGF. Symptomatic progression has been rare. Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT.
Is there a neurologist on this flight?
Sirven, Joseph I , Claypool, David W., Sahs, K. L., Wingerchuk, D. M., Bortz, Jennifer J., Drazkowski, Joseph F., Caselli, Richard J., Zanick, David

Mayo Clinic

Neurology | May 14, 2012 | Volume: 58 | Issue: 12 | Pages: 1739-1744

10.1212/wnl.58.12.1739 | PMID 12084870 Get It

A self-administered screener for migraine in primary care
Lipton, R.B. , Sadovsky, Richard, Kolodner, Ken, Hettiarachchi, J. , Dodick, David W. , Endicott, Jane , Harrison, William James

Mayo Clinic

Neurology | May 14, 2012 | Volume: 61 | Issue: 3 | Pages: 375-382

10.1212/01.wnl.0000078940.53438.83 | PMID 12913201 Get It

DHEA for Alzheimer’s disease
Knopman, David S. , Henderson, Victor W.

Mayo Clinic

Neurology | May 14, 2012 | Volume: 60 | Issue: 7 | Pages: 1060-1061

10.1212/01.wnl.0000059944.48810.3a | PMID 12682305 Get It